Individuals with Down syndrome are at risk for the development of Alzheimer's disease. This study seeks to explore if neurodegenerative biomarkers of this condition are present in childhood. In addition, this study will explore the possibility of these same biomarkers being present in children with autism spectrum disorder and other neurodevelopmental conditions.
To test the effectiveness of an addiction-based weight loss intervention, embodied first as a smartphone app with telephone coaching (AppCoach) compared to (1) addiction model based weight-loss app alone (App) and (2) multi-disciplinary in-clinic weight loss intervention (Clinic) on weight outcomes of overweight and obese adolescents at 3, 6, 12 and 18 months post enrollment.
We are studying how responses to the rotavirus vaccine are influenced by infant nutrition and other exposures in different areas of the world. The information we get from this study may help us to understand how to best protect infants from rotavirus and other infections.
Learn about the development of bacterial infections in shunted hydrocephalus.
The objective of this study is to learn how anemia may affect oxygen delivery to the brain as measured by magnetic resonance imaging (MRI). By studying this, we hope to better identify people who may benefit from correction of their anemia.
An investigation of the utility of non-invasive transcranial Doppler (TCD) ultrasound in the prediction of moyamoya disease in persons with Down syndrome with the goal of identifying cerebrovascular disease before it causes a stroke.
The overall objective is to assess the influences that repeated head impact accelerative events (both impact and nonimpact) and concussions have on high school athletes as measured by brain structure and function, cognition, and behavior.
Comparing brain MRIs, blood brain barrier integrity and cognitive performance in those with and without Long COVID symptoms and in those that have and have notbeen previously hospitalized with COVID.
The purpose of the study is to learn about how to improve access to care during young adulthood and to assess if telehealth is an acceptable form of care.
This study is a randomized, double-blind, active-controlled, titrated, parallel arm, multicenter study. It will compare the efficacy, safety and tolerability of twice daily Chronocort with twice daily IRHC (Cortef®) over a randomized treatment period of up to 52 weeks in participants aged 16 years and over with known classic CAH due to 21-hydroxylase deficiency. The primary efficacy assessment of biochemical responder rate and the key secondary assessments of dose responder rate and mean total daily dose will be assessed after 52 weeks of randomized treatment.
